Literature DB >> 27753623

Use of ghrelin in cachexia syndrome: a systematic review of clinical trials.

Jéssica V Mansson1, Fernanda D Alves1, Andréia Biolo1, Gabriela C Souza2.   

Abstract

CONTEXT: Ghrelin is a hormone that stimulates weight gain and increases appetite. For these reasons, it has been used for treatment of cachexia syndrome.
OBJECTIVE: The aim of this systematic review was to examine the use of ghrelin in cachexia patients to better understand the most prevalent clinical outcomes, particularly since the type and dosage of hormone used and the route and duration of administration often varies. DATA SOURCES: A search of electronic databases (MEDLINE, SciELO, Embase, Cochrane Library, and Clinical Trials.gov) was limited to original articles describing interventions in adult humans, with no limits for publication date or language. STUDY SELECTION: Articles were searched independently by 2 reviewers, from October 2013 to April 2015. Studies were eligible for inclusion if they were conducted in adult patients with a diagnosis of cachexia and provided information on type of ghrelin or analogue used, route of administration and dose administered, duration of intervention, outcomes, and clinical trial study design. DATA EXTRACTION: Data were extracted independently by 2 reviewers using a preconstructed spreadsheet. Initially, 573 references were identified. Seven articles describing 379 participants were selected for review.
RESULTS: Ghrelin was found to have a predominantly positive effect on growth hormone plasma levels, weight gain, increases in lean mass, and reductions in loss of adipose tissue.
CONCLUSIONS: Although the studies reviewed here report positive results, there is still little evidence available on the use of ghrelin to treat cachexia. Further research is required to determine conclusively whether the use of ghrelin in patients with cachexia is a viable therapy.
© The Author(s) 2016. Published by Oxford University Press on behalf of the International Life Sciences Institute. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  cachexia; ghrelin; systematic review; treatment

Mesh:

Substances:

Year:  2016        PMID: 27753623     DOI: 10.1093/nutrit/nuw029

Source DB:  PubMed          Journal:  Nutr Rev        ISSN: 0029-6643            Impact factor:   7.110


  5 in total

Review 1.  Energy metabolism in cachexia.

Authors:  Maria Rohm; Anja Zeigerer; Juliano Machado; Stephan Herzig
Journal:  EMBO Rep       Date:  2019-03-19       Impact factor: 8.807

2.  Development of a traditional Chinese medicine-based agent for the treatment of cancer cachexia.

Authors:  Kun-Chang Wu; Po-Chen Chu; Yu-Jung Cheng; Chia-Ing Li; Jingkui Tian; Hsing-Yu Wu; Szu-Hsien Wu; Yi-Chun Lai; Hsiang-Han Kao; Ao-Lin Hsu; Hsiang-Wen Lin; Chih-Hsueh Lin
Journal:  J Cachexia Sarcopenia Muscle       Date:  2022-06-19       Impact factor: 12.063

3.  Quinolones Modulate Ghrelin Receptor Signaling: Potential for a Novel Small Molecule Scaffold in the Treatment of Cachexia.

Authors:  Cristina Torres-Fuentes; Elena Pastor-Cavada; Rafael Cano; Dalia Kandil; Rachel Shanahan; Rocio Juan; Hamdy Shaban; Gerard P McGlacken; Harriët Schellekens
Journal:  Int J Mol Sci       Date:  2018-05-30       Impact factor: 5.923

4.  Systemic Delivery of hGhrelin Derivative by Lyophilizate for Dry Powder Inhalation System in Monkeys.

Authors:  Kahori Miyamoto; Yuko Ishibashi; Tomomi Akita; Chikamasa Yamashita
Journal:  Pharmaceutics       Date:  2021-02-07       Impact factor: 6.321

5.  Ghrelin regulates sepsis‑induced rat acute gastric injury.

Authors:  Bin Li; Qingling Lin; Hong Guo; Liping Liu; Yumin Li
Journal:  Mol Med Rep       Date:  2019-04-30       Impact factor: 2.952

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.